Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association
Top Cited Papers
Open Access
- 7 August 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain
- Vol. 131 (10) , 2553-2563
- https://doi.org/10.1093/brain/awn183
Abstract
The association of high levels of autoantibodies to glutamic acid decarboxylase (GAD-ab) and stiff-person syndrome (SPS) is well known. However, the full spectrum of neurological syndromes associated with GAD-ab is not well established. In addition, these patients usually present type 1 diabetes mellitus (DM1) that could justify the presence of high GAD-ab levels. To clarify these issues, we reviewed the clinical and immunological features of patients in whom high GAD-ab levels were detected in a reference centre for DM1 and for the detection of antineuronal antibodies in suspected paraneoplastic neurological syndromes (PNS). High GAD-ab levels were defined as values ≥2000 U/ml by radioimmunoassay. Intrathecal synthesis (IS) of GAD-ab was calculated in paired serum/CSF samples. Values higher than the IgG index were considered indicators for positive GAD-ab-specific IS. High GAD-ab levels were identified in 61 patients, 22 (36%) had SPS, 17 (28%) cerebellar ataxia, 11 (18%) other neurological disorders (epilepsy—four, PNS—four; idiopathic limbic encephalitis—two; myasthenia gravis—one), and 11 (18%) isolated DM1. Patients with SPS and cerebellar ataxia had the same frequency of female gender (86% vs 94%), DM1 (59% vs 53%), CSF oligoclonal bands (35% vs 69%). Three of the four PNS patients, with paraneoplastic encephalomyelitis, a predominant gait cerebellar ataxia, and limbic encephalitis, had neuroendocrine carcinomas. GAD expression was confirmed in the two tumours in which the study was done. The fourth patient presented with paraneoplastic cerebellar degeneration antedating a lung adenocarcinoma. The frequency of increased IS of GAD-ab was 85% in SPS, 100% in cerebellar ataxia, and 86% in other neurological disorders. In conclusion, our study emphasizes that high GAD-ab levels associate with other neurological disorders besides SPS. Cerebellar ataxia, the second most common syndrome associated with high GAD-ab levels, shares with SPS the same demographic, clinical and immunological features. The demonstration of an increased IS of GAD-ab is important to confirm that the GAD autoimmunity is related to the neurological syndrome particularly when there is a concomitant DM1 that could justify the presence of high GAD-ab levels. Lastly, in patients who develop neurological syndromes that suggest a PNS, the finding of GAD-ab does not rule out this possibility and appropriate studies should be done to confirm an underlying cancer.Keywords
This publication has 57 references indexed in Scilit:
- GAD antibody positive paraneoplastic stiff person syndrome in a patient with renal cell carcinomaMovement Disorders, 2007
- Antibodies to CRMP3–4 associated with limbic encephalitis and thymomaClinical and Experimental Immunology, 2007
- Selective loss of Purkinje cells in a patient with anti-glutamic acid decarboxylase antibody-associated cerebellar ataxiaJournal of Neurology, Neurosurgery & Psychiatry, 2007
- Epilepsy and cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodiesJournal of Neurology, Neurosurgery & Psychiatry, 2007
- Antigenic differences between neurological and diabetic patients with anti‐glutamic acid decarboxylase antibodiesEuropean Journal of Neurology, 2005
- Autoantibody Profiles and Neurological Correlations of ThymomaClinical Cancer Research, 2004
- Anticardiolipin, glutamic acid decarboxylase, and antinuclear antibodies in epileptic patientsClinical and Experimental Medicine, 2003
- Autoimmunity to glutamic acid decarboxylase (GAD) in stiffman syndrome and insulin-dependent diabetes mellitusTrends in Neurosciences, 1991
- Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylaseNature, 1990
- Autoantibodies to GABA-ergic Neurons and Pancreatic Beta Cells in Stiff-Man SyndromeNew England Journal of Medicine, 1990